目的·系统评价托吡酯减轻非典型抗精神病药所致体质量增加的作用。方法·计算机检索中国知网、万方数据库、中国生物医学文献服务系统、Cochrane Library 以及PubMed、Embase、PsycINFO数据库，检索文献起始时间不限、截止时间为2019年3月。收集关于托吡酯减轻非典型抗精神病药关联的体质量增加的随机对照试验。由2名研究者独立进行文献筛选、资料提取和文献质量评价后，采用RevMan 5.3软件进行meta分析。结果·最终纳入20篇随机对照研究，共有1 024例患者。Meta分析结果显示：托吡酯能够有效改善非典型抗精神病药所致的体质量增加，其差异有统计学意义[加权均数差（weighted mean difference, WMD） -4.09, 95% CI -5.74～-2.44，P0.000]；体质量指数（body mass index，BMI）也有明显的改善（WMD-2.42, 95% CI -3.02～-1.82，P0.000）。结论·托吡酯能有效改善非典型抗精神病药所引起的体质量增加及BMI的增加。

Objective · To systematically evaluate the effect of topiramate on reducing body weight increase causedatypical antipsychotic drugs. Methods · A literature search was performedusing PubMed database, Embase database, PsycINFO database, Cochrane Library, CNKI, WanFang data and SinoMed. Randomized placebo-controlled trials of topiramate targeting weight-gain causedatypical antipsychotic drugs inception to Mar. 2019. Two researchers independently screened literatures according to the inclusion and exclusion criteria, extracted data, and assessed methodological quality of included studies. The meta-analysis was performed using RevMan 5.3 software. Results · A total of 20 randomized controlled trials were included, consisting of 1 024 subjects. The results of meta-analysis showed that topiramate was significant effective in reducing atypical antipsychotic-related weight gain [weighted mean difference (WMD)-4.09, 95% CI -5.74 - -2.44, P0.000]. The body mass index (BMI) was also improved significantly (WMD-2.42, 95% CI -3.02 - -1.82, P0.000). Conclusion · Topiramate can effectively improve the body weight and BMI increase causedatypical antipsychotic drugs.